Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
MO07 - NSCLC - Targeted Therapies II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:T. John
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO07.01 - Clinical benefit of continuing crizotinib beyond initial disease progression in patients with advanced ALK-positive non-small-cell lung cancer
16:15 - 16:20 | Author(s): S.I. Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO07.07 - Combined pan-ERBB and ALK/ROS1/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer (NSCLC): update of a phase I trial
16:50 - 16:55 | Author(s): G. Giaccone
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-011 - A Phase Ib study of high-dose intermittent (HDI) afatinib in EGFR T790M mutation-positive non-small cell lung cancer patients with acquired resistance to reversible EGFR TKIs
09:30 - 09:30 | Author(s): D..R. Camidge
- Abstract
Loading... -
+
P2.11-032 - Patient Report of Dacomitinib (PF-00299804)-Associated Symptom and HRQoL Benefit in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): J.P. Doherty
- Abstract
Loading...
-
+
Best of Posters - IASLC Selection - Part 1
- Type: Exhibit Showcase Session
- Track:
- Presentations: 4
- Coordinates: 10/29/2013, 09:55 - 10:25, Exhibit Hall, Ground Level
-
+
P1.11-032 - Results with dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancers
10:00 - 10:05 | Author(s): M.G. Kris
- Abstract
Loading...
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.02 - Efficacy of standard care for second-line advanced non-small cell lung cancer (NSCLC) by KRAS mutation status: observations on MEK inhibitor enhancement of chemotherapy
10:40 - 10:50 | Author(s): P.A. Jänne
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO15 - Novel Genes and Pathways
- Type: Mini Oral Abstract Session
- Track: Biology
- Presentations: 12
- Moderators:Y. Ohe
- Coordinates: 10/29/2013, 16:15 - 17:45, Parkside Ballroom A, Level 1
-
+
MO15.06 - A prospective internet-based study of patients with lung cancer harboring baseline EGFR T790M to identify germline carriers and characterize familial risk
16:40 - 16:45 | Author(s): G.R. Oxnard
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO18 - NSCLC - Targeted Therapies IV
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 13
- Moderators:L. Horn
- Coordinates: 10/29/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO18.12 - Impact of KRAS codon sub-types in a Phase II second-line trial in KRAS-mutant advanced non-small cell lung cancer (NSCLC) of selumetinib plus docetaxel versus docetaxel alone
17:20 - 17:25 | Author(s): T. Liptrot
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-003 - Correlative Analysis of Circulating Biomarkers from a Phase 1b/2 trial of Cabozantinib (C) with or without Erlotinib (E) in Patients (Pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): S.K. Padda
- Abstract
Loading... -
+
P3.06-054 - Development of a clinical-grade quantitative assay for non-invasive measurement of tumor genotype in cell-free plasma DNA (cfDNA) using next-generation quantitative genotyping
09:30 - 09:30 | Author(s): G.R. Oxnard
- Abstract
Loading...
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-028 - Exploration of the relationship between neutrophil count and clinical consequences in patients with advanced non-small cell lung cancer (NSCLC) receiving selumetinib plus docetaxel: predicted effect of primary prophylactic GCSF
09:30 - 09:30 | Author(s): P.A. Jänne
- Abstract
Loading... -
+
P3.11-029 - The SELECT-1 study design: selumetinib in combination with docetaxel for second-line treatment of KRAS mutation-positive locally advanced or metastatic non-small cell lung cancer
09:30 - 09:30 | Author(s): P.A. Jänne
- Abstract
Loading...
-
+
P3.12 - Poster Session 3 - NSCLC Early Stage
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 25
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.12-004 - A practice-based analysis to gauge the feasibility of genotype-directed induction therapy for stage III non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): J. Varon
- Abstract
Loading...
-
+
MO21 - Prognostic and Predictive Biomarkers V - EGFR
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:D.C. Lam
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
MO21.12 - AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC
11:30 - 11:35 | Author(s): M. Ranson
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
